Anavex Life Sciences Corp.
AVXL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001314052
No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.
Holders of 5% or more of AVXL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Anavex Life Sciences Corp., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 5.03%4.66M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Anavex Life Sciences Corp., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 20269:54 AM ET | Vanguard Capital Management LLC | 13G | 5.03%4.66M shares | New | Jun 30, 2026 | SEC |
| Mar 26, 20263:45 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | State Street Corp | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Park West Asset Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 2, 20213:13 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Anavex Life Sciences Corp. shares.
No Form 144 notices for Anavex Life Sciences Corp. are on file.